Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | EVP, Chief Medical Officer | November 16, 2023 | November 20, 2023 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Medical Officer | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date November 16, 2023 · Filed November 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 171,284 |
Reported balance
After 2023-11-16 transaction · row 1
1 source rowRow 1 · 2023-11-16 · Sale · Disposed 12,287 · Balance 171,284 F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
F2: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.
RHYTHM PHARMACEUTICALS, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $115.44 · Expires 2036-08-16 | Direct | 50,000 |
Reported balance
After 2026-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 50,000 · Balance 50,000 F1: The Stock Options vest and become exercisable as to 25% of the total number of shares subject to the option on the first anniversary of the grant date and as to 6.25% of the total number of shares subject to the option upon the Reporting Person's completion of each successive three months of service to the Corporation. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 25,000 |
Reported balance
After 2026-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-17 · Grant · Acquired 25,000 · Balance 25,000 F2: The Restricted Stock Units vest as to 25% of the Restricted Stock Units on September 1 of each of 2027, 2028, 2029, and 2030, such that the Restricted Stock Units shall be fully vested on September 1, 2030, subject to the Reporting Person continuing in service through each such vesting date. F3: The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options vest and become exercisable as to 25% of the total number of shares subject to the option on the first anniversary of the grant date and as to 6.25% of the total number of shares subject to the option upon the Reporting Person's completion of each successive three months of service to the Corporation.
F2: The Restricted Stock Units vest as to 25% of the Restricted Stock Units on September 1 of each of 2027, 2028, 2029, and 2030, such that the Restricted Stock Units shall be fully vested on September 1, 2030, subject to the Reporting Person continuing in service through each such vesting date.
F3: The restricted stock units have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date May 18, 2026 · Filed May 18, 2026
Section 16 reporting ended · disclosed 2026-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Disposition to issuer · Disposed 20,171 · Balance 0 F1: These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.31 · Expires 2035-11-10 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Disposition to issuer · Disposed 72,321 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.65 · Expires 2036-01-21 | Direct | 0 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Disposition to issuer · Disposed 4,700 · Balance 0 F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration").
F2: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001649904-26-000020 · form4.xml · derivative · entry 2 Joshi Manher · CIK 0001978048 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F2 · derivative.exercise_date: The Restricted Stock Units vest as to 25% of the Restricted Stock Units on September 1 of each of 2027, 2028, 2029, and 2030, such that the Restricted Stock Units shall be fully vested on September 1, 2030, subject to the Reporting Person continuing in service through each such vesting date. F3 · derivative.expiration_date: The restricted stock units have no expiration date. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 21:35 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $115.44 | $0.00 |
DisclosureSEC source: 0001649904-26-000020 · form4.xml · derivative · entry 1 Joshi Manher · CIK 0001978048 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-08-16 F1 · derivative.exercise_date: The Stock Options vest and become exercisable as to 25% of the total number of shares subject to the option on the first anniversary of the grant date and as to 6.25% of the total number of shares subject to the option upon the Reporting Person's completion of each successive three months of service to the Corporation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:39 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 4,700 | Not disclosed Strike: $43.65 | Not disclosed |
DisclosureSEC source: 0001978048-26-000002 · form4-05182026_080547.xml · derivative · entry 3 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,700 shares Expires 2036-01-21 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:39 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerStock Option (Right to buy) · Derivative | 72,321 | Not disclosed Strike: $46.31 | Not disclosed |
DisclosureSEC source: 0001978048-26-000002 · form4-05182026_080547.xml · derivative · entry 2 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,321 shares Expires 2035-11-10 F3 · price: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. F3 · derivative.exercise_date: At the effective time of the Merger, this option was cancelled in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of shares covered by the option as of immediately prior to such cancellation. Read SEC document |
| May 18, 2026 Filed May 18, 2026 20:39 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Disposition to issuerCommon Stock | 20,171 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001978048-26-000002 · form4-05182026_080547.xml · nonDerivative · entry 1 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: These shares are represented by previously reported restricted stock units ("RSUs"). Pursuant to the Agreement and Plan of Merger, dated as of April 5, 2026, by and among Soleno Therapeutics, Inc. (the "Company"), Neocrine Biosciences, Inc. ("Parent") and Sigma Merger Sub, Inc. ("Merger Sub"), on May 18, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, each issued and outstanding vested and unvested RSU was cancelled and converted into the right to receive an amount equal to $53.00 in cash (the "Merger Consideration"). F2 · price: In connection with the Merger, each issued and outstanding share of the Company's Common Stock was cancelled and converted into the right to receive an amount in cash equal to the Merger Consideration. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 23:04 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantEmployee stock option (right to buy) · Derivative | 4,700 | $0.00 Strike: $43.65 | $0.00 |
DisclosureSEC source: 0001978048-26-000001 · form4-01232026_110157.xml · derivative · entry 2 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,700 Underlying: Common Stock · 4,700 shares Expires 2036-01-21 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 23:04 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 4,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001978048-26-000001 · form4-01232026_110157.xml · nonDerivative · entry 1 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,171 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date. F2 · balance_after: These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 22:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 72,321 | $0.00 Strike: $46.31 | $0.00 |
DisclosureSEC source: 0001978048-25-000003 · form4-11122025_101105.xml · derivative · entry 2 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,321 Underlying: Common Stock · 72,321 shares Expires 2035-11-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One-fourth of the shares subject to the option shall vest on November 10, 2026 and one forty-eighth of the shares subject to the option shall vest each month thereafter on the same day of the month, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 22:21 UTC | SOLENO THERAPEUTICS INC SLNO · Entity 46432 | GrantCommon Stock | 16,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001978048-25-000003 · form4-11122025_101105.xml · nonDerivative · entry 1 Joshi Manher · CIK 0001978048 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,071 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 10, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. F1 · balance_after: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. One-half of the RSUs shall vest on November 10, 2026 and one third of the remaining RSUs shall vest each one-year anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 22:30 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 12,287 | $0.39 | $4,779.64 |
DisclosureSEC source: 0000905148-23-001510 · form4.xml · nonDerivative · entry 1 Joshi Manher · CIK 0001978048 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,284 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,773 | $1.65 | $6,236.77 |
DisclosureSEC source: 0001140361-23-040560 · form4.xml · nonDerivative · entry 2 Joshi Manher · CIK 0001978048 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,571 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,202 | $1.65 | $5,289.70 |
DisclosureSEC source: 0001140361-23-040560 · form4.xml · nonDerivative · entry 1 Joshi Manher · CIK 0001978048 · EVP, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,344 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.